Cargando…

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease

Detalles Bibliográficos
Autores principales:	An, Seong Soo A., Hulme, John P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360110/ https://www.ncbi.nlm.nih.gov/pubmed/37282463 http://dx.doi.org/10.4103/1673-5374.371361

Ejemplares similares

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
por: Reddy, P. Hemachandra, et al.
Publicado: (2019)

The biogenesis and biology of amyloid β oligomers in the brain
por: Ashe, Karen Hsiao
Publicado: (2020)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Phosphorylation of amyloid beta (Aβ) peptides – A trigger for formation of toxic aggregates in Alzheimer's disease
por: Kumar, Sathish, et al.
Publicado: (2011)

Mechanosensitivity of N-methyl-D-aspartate receptors (NMDAR) is the key through which amyloid beta oligomers activate them
por: Fani, Giulia, et al.
Publicado: (2021)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
por: Kim, Keun You, et al.
Publicado: (2022)

Enhanced neuronal degradation of amyloid-β oligomers allows synapse regeneration
por: Bate, Clive
Publicado: (2015)

The tip of the iceberg? The underestimated potential of non-canonical beta-amyloids for Alzheimer’s disease
por: Busch, Lukas, et al.
Publicado: (2023)

Immunogenic properties of amyloid beta oligomers
por: Dalgediene, Indre, et al.
Publicado: (2013)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer’s Disease
por: Kang, Heeyoung, et al.
Publicado: (2021)

Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?
por: Menéndez González, Manuel
Publicado: (2017)

Beta‐amyloid 1‐42 monomers, but not oligomers, produce PHF‐like conformation of Tau protein
por: Manassero, Giusi, et al.
Publicado: (2016)

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
por: Sardar Sinha, Maitrayee, et al.
Publicado: (2018)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Small molecules to target tau amyloid aggregation
por: Manglano-Artuñedo, Zoe, et al.
Publicado: (2023)

Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease
por: Meng, Xue, et al.
Publicado: (2019)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
por: Gibbs, Ebrima, et al.
Publicado: (2019)

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease
por: Ding, Yu, et al.
Publicado: (2019)

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer’s disease
por: Wang, Liang, et al.
Publicado: (2022)

Beta‐amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease
por: Pannuzzo, Martina
Publicado: (2021)

Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure
por: Yang, YoungSoon, et al.
Publicado: (2018)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Cyclic adenosine monophosphate-elevating agents inhibit amyloid-beta internalization and neurotoxicity: their action in Alzheimer’s disease prevention
por: Gopalakrishna, Rayudu, et al.
Publicado: (2023)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
por: Broersen, Kerensa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6tn7n5ijas6dottp3mglq6gfri